risedronic acid

Chemical data

Formula

C7H11NO7P2

Molecular weight

283.11 g/mol

IUPAC name

(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid

SMILES

C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O

InChIKey

IIDJRNMFWXDHID-UHFFFAOYSA-N

XLogP

-3.1

Polar surface area

148 Ų

H-bond donors

5

H-bond acceptors

8

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Approved

Molecule type

Small molecule

First approval

1998

Admin. routes

oral

Indications

osteoporosis, postmenopausal osteoporosis, Osteopenia, metastatic prostate cancer

via ChEMBL · EBI

• Osteoporosis in elderly: prevention and treatment.Clinics in geriatric medicine · 2002
• Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.Clinical drug investigation · 2009
• Risedronate.Drugs & aging · 1998
• Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.Clinical drug investigation · 2006
• Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.Investigational new drugs · 2021

via PubMed

Wikidata facts

Subclass of

bisphosphonate

Mass

283.001

Has use

medication

via Wikidata · CC0